X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 71.69 CNY -3.54% Market Closed
Market Cap: 29.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Xiamen Amoytop Biotech Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Gross Profit
ÂĄ2B
CAGR 3-Years
40%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Gross Profit
ÂĄ14.7B
CAGR 3-Years
108%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Gross Profit
ÂĄ4.5B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Gross Profit
ÂĄ3.3B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
22%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Gross Profit
ÂĄ11.7B
CAGR 3-Years
3%
CAGR 5-Years
26%
CAGR 10-Years
38%
Imeik Technology Development Co Ltd
SZSE:300896
Gross Profit
ÂĄ2.7B
CAGR 3-Years
61%
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.2B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
86.96 CNY
Undervaluation 18%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's Gross Profit?
Gross Profit
2B CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Gross Profit amounts to 2B CNY.

What is Xiamen Amoytop Biotech Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
38%

Over the last year, the Gross Profit growth was 44%. The average annual Gross Profit growth rates for Xiamen Amoytop Biotech Co Ltd have been 40% over the past three years , 38% over the past five years .

Back to Top